×
About 730 results

ALLMedicine™ Retinoschisis Center

Research & Reviews  279 results

Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis
https://clinicaltrials.gov/ct2/show/NCT00055029

May 13th, 2022 - Objectives: The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease. The specific primary objectives of this study are to: 1. Investiga...

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
https://clinicaltrials.gov/ct2/show/NCT02317887

May 13th, 2022 - Objective: To evaluate the safety and tolerability of ocular AAV-RS1 vector (AAV8-scRS/IRBPhRS) gene transfer to the retina of participants affected with X-linked juvenile retinoschisis (XLRS). Study Population: Male participants affected with XLR...

An evidence-based review of the epidemiology of myopic traction maculopathy.
https://doi.org/10.1016/j.survophthal.2022.03.007
Survey of Ophthalmology; Cheong KX, Xu L et. al.

Apr 4th, 2022 - Myopic traction maculopathy (MTM), one of the complications of pathologic myopia, is a spectrum of pathological conditions that are attributed to tractional changes in the eye characterized by retinoschisis, lamellar or full thickness macular hole...

Surgical Outcomes of Progressive Retinoschisis-Related Retinal Detachments: A 17-Year S...
https://doi.org/10.3928/23258160-20220211-03
Ophthalmic Surgery, Lasers & Imaging Retina; Liao A, Barnett J et. al.

Mar 12th, 2022 - To provide an overview of progressive retinoschisis-related retinal detachment (RSRD) management at a tertiary referral center. Single-institution retrospective case series from January 1, 2003, to May 1, 2020. Progressive RSRD occurred in 0.9% of...

see more →

Clinicaltrials.gov  8 results

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
https://clinicaltrials.gov/ct2/show/NCT02317887

May 13th, 2022 - Objective: To evaluate the safety and tolerability of ocular AAV-RS1 vector (AAV8-scRS/IRBPhRS) gene transfer to the retina of participants affected with X-linked juvenile retinoschisis (XLRS). Study Population: Male participants affected with XLR...

Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis
https://clinicaltrials.gov/ct2/show/NCT00055029

May 13th, 2022 - Objectives: The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease. The specific primary objectives of this study are to: 1. Investiga...

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
https://clinicaltrials.gov/ct2/show/NCT02416622

Jul 14th, 2020 - This will be a non-randomized, open label, Phase 1/2 dose escalation study. Up to 27 participants will be enrolled. Each participant will receive the study agent by intravitreal injection in one eye on a single occasion. Enrollment will begin with...

Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy
https://clinicaltrials.gov/ct2/show/NCT04278079

Feb 20th, 2020 - Performing pars plana vitrectomy for highly myopic patients with decreased visual acuity is the standard of care for patients with myopic traction. A variety of findings are seen by Optical Coherence Tomography. Epiretinal membranes, retinoschisis...

People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02317354

Dec 9th, 2019 - Objective: The objective of this study is to understand the factors that influence patient expectations when enrolling in an early-phase RS1 ocular gene transfer clinical trial and to assess the psychological impact of patient expectations over ti...

see more →

News  5 results

A Boy With Suddenly Failing Vision
https://www.medscape.com/viewarticle/895120_2

Apr 18th, 2018 - Case Diagnosis X-linked retinoschisis (XLRS), an inherited mutation that causes early-onset retinoschisis, or splitting of the retina, is the correct diagnosis. The affected RS1 gene, which encodes the protein retinoschisin, causes a disruption of...

Biogen enters eye-treatment arena with AGTC deal
https://www.reuters.com/article/us-biogen-agtc/biogen-enters-eye-treatment-arena-with-agtc-deal-idUSKCN0PC1KR20150702

Jul 2nd, 2015 - (Reuters) - Biogen said on Thursday it had forged a deal with AGTC to develop gene-based therapies for a range of eye diseases, marking the company’s entry into opthalmology. Shares of AGTC, formally known as Applied Genetic Technologies Corp, sur...

An Unresponsive Baby Boy
https://www.medscape.com/viewarticle/732780

Nov 24th, 2010 - Clinical Presentation A previously healthy 10-month-old boy presented to the emergency department after his mother found him unresponsive at home. He had been under the care of his aunt's boyfriend, who admitted to police that he had shaken the pa...

New FDA Orphan Drugs: AMT 011, Axitinib, Gene Therapy for Juvenile Retinoschisis
https://www.medscape.com/viewarticle/558018

Jun 9th, 2007 - June 8, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for AMT 011 for the treatment of lipoprotein lipase deficiency, axitinib for the treatment of pancreatic cancer, and adeno-associated viral vector express...

Vitreomacular Interface Diseases
https://www.medscape.com/viewarticle/772188_4

Pathophysiology of Vitreomacular Traction In symptomatic VMA, the continuous tangential and antero posterior stretching on the macula can lead to VMT, which, if allowed to progress, can lead to sight-threatening complications, such as the formatio...

see more →